Teladoc Health Q3 2026 earnings
Revenue down 3% year-over-year; adjusted EBITDA up 14% to $79.4 million; net loss narrowed to $26.9 million.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $605.1 million | -3% | — | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.15 | +46% | — | Ex. 99.1, income statement |
| EPS (adjusted) | -$0.15 | +46% | — | Ex. 99.1, income statement |
| Net income | -$26.9 million | +46% | — | Ex. 99.1, income statement |
| Adj. EBITDA | $79.4 million | +14% | — | Ex. 99.1, income statement |
| Adj. EBITDA margin | 13.1% | +2.2 pp | — | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Integrated Care | $398.5 million | +2% | 66% | Adjusted EBITDA margin 18.8% |
| BetterHelp | $206.6 million | -13% | 34% | Adjusted EBITDA margin 2.2% |
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $633.2 million (+6% YoY)
- One-offs in the quarter Restructuring costs $4.4 million; Legal settlement costs and recoveries, net $0.6 million
- Effective tax rate 2.4% (prior-year -1.4%, year-to-date 3.7%)
- Non-GAAP bridge Adds back amortization of intangibles ($88.3M), stock-based compensation ($11.6M), restructuring costs ($4.4M), acquisition/integration costs ($1.6M), legal settlement costs ($0.6M), depreciation, interest, and other items
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash flow from operations | $106.5 million | $64.7 million | $99.3 million | +64% QoQ, +7% YoY |
| Free cash flow | $75.9 million | $35.7 million | $67.9 million | +112% QoQ, +12% YoY |
| Capex | $30.5 million | $28.9 million | $31.3 million | +5% QoQ, -2% YoY |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Full Year 2026 Revenue | $2,395 - $2,441 million | $2,362 - $2,447 million | Lowered range |
| Full Year 2026 Adjusted EBITDA | $277 - $303 million | $271 - $303 million | Raised midpoint |
| Full Year 2026 Net loss per share | ($0.95) - ($0.75) | ($1.00) - ($0.75) | Raised midpoint |
| Full Year 2026 Free Cash Flow | $135 - $165 million | $130 - $170 million | Lowered range |
| 4Q 2026 Revenue | $569 - $615 million | $569 - $609 million | Raised range |
| 4Q 2026 Adjusted EBITDA | $74 - $100 million | $62 - $74 million | Raised range |
| 4Q 2026 Net loss per share | ($0.23) - ($0.03) | ($0.30) - ($0.20) | Raised range |
What drove it
- Revenue story Integrated Care revenue up 2% to $398.5 million; BetterHelp revenue down 13% to $206.6 million; Access fees down 10% to $466.7 million; Other revenue up 31% to $138.4 million.
- EPS story Net loss per share narrowed to $0.15 from $0.28 YoY, driven by lower operating losses and a favorable tax rate.
- One-off check Restructuring costs $4.4 million; Legal settlement costs and recoveries, net $0.6 million
The good
- Adjusted EBITDA up 14% to $79.4 million
- Net loss narrowed to $26.9 million
- Cash flow from operations $106.5 million
- Free cash flow $75.9 million
The bad
- BetterHelp revenue down 13% to $206.6 million
- Access fees revenue down 10% to $466.7 million
- U.S. revenue down 4% to $489.2 million
The ugly
- none
Open questions
- The filing does not disclose the specific amount of the legal settlement costs and recoveries, net.
- The filing does not disclose the specific amount of the discrete tax benefit related to the research and development tax credit study.
Full release
Earnings: TDOC — filed 2026-10-28
Teladoc Health Reports Third Quarter 2026 Results
NEW YORK, October 28, 2026 — Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2026 (“Third Quarter 2026”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2025 (“Third Quarter 2025”).
Highlights
• Third Quarter 2026 revenue of $605.1 million, down 3% year-over-year
• Third Quarter 2026 net loss of $26.9 million, or $0.15 per share
• Third Quarter 2026 adjusted EBITDA of $79.4 million, up 14% year-over-year
• Integrated Care segment revenue of $398.5 million, up 2% year-over-year, and adjusted EBITDA margin of 18.8%
• BetterHelp segment revenue of $206.6 million, down 13% year-over-year, and adjusted EBITDA margin of 2.2%
“We delivered third quarter results near the upper end of our guidance range for consolidated revenue and above our range for consolidated adjusted EBITDA, reflecting solid execution across our two segments,” said Chuck Divita, Chief Executive Officer of Teladoc Health.
“Within the Integrated Care segment, we continue to advance our innovation agenda, including the implementation of Teladoc One with our early launch partners, while also expanding our capabilities through initiatives such as hybrid care and AI-enabled solutions. In the BetterHelp segment, insurance revenue exceeded our expectations, and we are making encouraging progress expanding provider capacity and scaling access to covered services. While there is more work ahead, we remain focused on disciplined execution against our strategic priorities. The actions we are taking are showing traction, and we believe will position us well for the opportunities ahead.”
See note (1) in the Notes section that follows.
Third Quarter 2026
Revenue decreased 3% to $605.1 million from $626.4 million in Third Quarter 2025. Access fees revenue decreased 10% to $466.7 million while other revenue increased 31% to $138.4 million. U.S. revenue decreased 4% to $489.2 million while International revenue decreased 1% to $115.9 million.¹
Integrated Care segment revenue increased 2% to $398.5 million in Third Quarter 2026 while BetterHelp segment revenue decreased 13% to $206.6 million, reflecting continued actions to prioritize Insurance Covered Services and the continuing decline in users paying directly out of pocket.
Net loss totaled $26.9 million, or $0.15 per share, for Third Quarter 2026, compared to $49.5 million, or $0.28 per share, for Third Quarter 2025. Results for Third Quarter 2026 included amortization of intangibles of $88.3 million, or $0.49 per share pre-tax, stock-based compensation expense of $11.6 million, or $0.06 per share pre-tax, and restructuring costs related to severance costs and costs associated with office space reductions of $4.4 million, or $0.02 per share pre-tax.
Results for Third Quarter 2025 included amortization of intangibles of $85.8 million, or $0.48 per share pre-tax, stock-based compensation expense of $17.0 million or $0.10 per share pre-tax, and a non-cash goodwill impairment charge of $12.6 million, or $0.07 per share pre-tax. Net loss for Third Quarter 2025 also included restructuring costs related to severance costs and costs associated with office space reductions of $2.0 million, or $0.01 per share pre-tax. The non-cash goodwill impairment charge recorded in Third Quarter 2025 w as the result of the fair value of the Integrated Care segment being less than its carrying value at the time of the acquisition of Telecare Australia Pty Ltd ("Telecare").
Adjusted EBITDA
Financial statements
Income Statement (In thousands, except per share data, unaudited)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Change | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | Change | ||
|---|---|---|---|---|---|---|---|
| (In thousands, except per share data, unaudited) | Revenue | 605,102 | 626,439 | -3 | 1,825,874 | 1,887,708 | -3 |
| (In thousands, except per share data, unaudited) | Net loss | -26,934 | -49,507 | 46 | -129,679 | -175,179 | 26 |
| (In thousands, except per share data, unaudited) | Net loss per share | -0.15 | -0.28 | 46 | -0.72 | -1 | 28 |
| (In thousands, except per share data, unaudited) | Adjusted EBITDA (1) | 79,358 | 69,909 | 14 | 203,240 | 197,313 | 3 |
Income Statement
The outlook provided below is based on current market conditions and expectations and what we know today.
| Full Year 2026 Outlook Range | ||
|---|---|---|
| For the full year of 2026, we expect: | Revenue | $2,395 - $2,441 million |
| For the full year of 2026, we expect: | Adjusted EBITDA | $277 - $303 million |
| For the full year of 2026, we expect: | Net loss per share | ($0.95) - ($0.75) |
| For the full year of 2026, we expect: | Free Cash Flow | $135 - $165 million |
| For the full year of 2026, we expect: | U.S. Integrated Care Members (2) | 99.5 - 100.5 million |
| Integrated Care | Revenue growth percentage (year-over-year) | 1.1% - 2.1% |
| Integrated Care | Adjusted EBITDA margin | 16.0% - 16.6% |
| BetterHelp | Revenue growth percentage (year-over-year) | (16.1%) - (12.9%) |
| BetterHelp | Adjusted EBITDA margin | 2.7% - 4.3% |
Income Statement
For the fourth quarter of 2026, we expect: — The outlook provided below is based on current market conditions and expectations and what we know today.
| For the fourth quarter of 2026, we expect: – 4Q 2026 Outlook Range | ||
|---|---|---|
| Revenue | $569 - $615 million | |
| Adjusted EBITDA | $74 - $100 million | |
| Net loss per share | ($0.23) - ($0.03) | |
| U.S. Integrated Care Members (2) | 99.5 - 100.5 million | |
| Integrated Care | Revenue growth percentage (year-over-year) | 0.0% - 3.8% |
| Integrated Care | Adjusted EBITDA margin | 14.5% - 16.8% |
| BetterHelp | Revenue growth percentage (year-over-year) | (31.5%) - (18.5%) |
| BetterHelp | Adjusted EBITDA margin | 9.2% - 15.1% |
Income Statement
Three Months Ended September 30, — (In thousands, except share and per share data, unaudited)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenue | 605,102 | 626,439 | 1,825,874 | 1,887,708 | |
| Costs and expenses: | Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 190,258 | 187,179 | 578,621 | 574,545 |
| Costs and expenses: | Advertising and marketing | 123,978 | 167,985 | 418,902 | 503,717 |
| Costs and expenses: | Sales | 49,578 | 48,209 | 150,245 | 146,853 |
| Costs and expenses: | Technology and development | 65,546 | 67,572 | 196,272 | 206,314 |
| Costs and expenses: | General and administrative | 107,400 | 102,581 | 313,522 | 323,469 |
| Costs and expenses: | Goodwill impairment | 12,625 | 71,763 | ||
| Costs and expenses: | Acquisition, integration, and transformation costs | 1,565 | 1,931 | 4,319 | 6,777 |
| Costs and expenses: | Restructuring costs | 4,404 | 1,950 | 17,283 | 11,989 |
| Costs and expenses: | Amortization of intangible assets | 88,286 | 85,757 | 266,554 | 258,725 |
| Costs and expenses: | Depreciation of property and equipment | 2,186 | 2,612 | 7,115 | 10,514 |
| Costs and expenses: | Total costs and expenses | 633,201 | 678,401 | 1,952,833 | 2,114,666 |
| Costs and expenses: | Loss from operations | -28,099 | -51,962 | -126,959 | -226,958 |
| Costs and expenses: | Interest income | -7,040 | -7,081 | -20,011 | -29,819 |
| Costs and expenses: | Interest expense | 4,935 | 4,526 | 15,412 | 14,764 |
| Costs and expenses: | Other expense (income), net | 285 | 815 | 2,672 | -9,991 |
| Costs and expenses: | Loss before provision for income taxes | -26,279 | -50,222 | -125,032 | -201,912 |
| Costs and expenses: | Provision for income taxes | 655 | -715 | 4,647 | -26,733 |
| Costs and expenses: | Net loss | -26,934 | -49,507 | -129,679 | -175,179 |
| Costs and expenses: | Net loss per share, basic and diluted | -0.15 | -0.28 | -0.72 | -1 |
| Costs and expenses: | Weighted-average shares used to compute basic and diluted net loss per share | 181,876,281 | 176,934,781 | 180,684,939 | 175,678,949 |
Income Statement
Three Months Ended September 30, — Compensation expense for stock-based awards was classified as follows (in thousands, unaudited):
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Cost of revenue (exclusive of depreciation and amortization, which are shown separately) | 104 | 509 | 575 | 1,588 |
| Advertising and marketing | 471 | 1,083 | 1,757 | 3,888 |
| Sales | 1,545 | 3,156 | 5,082 | 11,009 |
| Technology and development | 2,066 | 4,129 | 6,528 | 14,161 |
| General and administrative | 7,430 | 8,119 | 21,586 | 33,857 |
| Total stock-based compensation expense (3) | 11,616 | 16,996 | 35,528 | 64,503 |
Income Statement
Three Months Ended — Revenues (in thousands)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Change | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | Change | ||
|---|---|---|---|---|---|---|---|
| Access Fees | 466,721 | 520,907 | -10 | 1,425,591 | 1,570,346 | -9 | |
| Other | 138,381 | 105,532 | 31 | 400,283 | 317,362 | 26 | |
| Total Revenue | 605,102 | 626,439 | -3 | 1,825,874 | 1,887,708 | -3 | |
| Revenue by Geography | U.S. | 489,214 | 509,774 | -4 | 1,468,079 | 1,554,433 | -6 |
| Revenue by Geography | International | 115,888 | 116,665 | -1 | 357,795 | 333,275 | 7 |
| Revenue by Geography | Total Revenue | 605,102 | 626,439 | -3 | 1,825,874 | 1,887,708 | -3 |
Income Statement
(In thousands, unaudited) (in thousands)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | Outlook in millions (8) – Fourth Quarter – 2026 | Outlook in millions (8) – Full Year – 2026 | ||
|---|---|---|---|---|---|---|---|
| Net loss | -26,934 | -49,507 | -129,679 | -175,179 | $(42) - (5) | $(172) - (136) | |
| Add: | Provision for income taxes | 655 | -715 | 4,647 | -26,733 | ||
| Add: | Other expense (income), net | 285 | 815 | 2,672 | -9,991 | ||
| Add: | Interest expense | 4,935 | 4,526 | 15,412 | 14,764 | ||
| Add: | Interest income | -7,040 | -7,081 | -20,011 | -29,819 | ||
| Add: | Depreciation of property and equipment | 2,186 | 2,612 | 7,115 | 10,514 | ||
| Add: | Amortization of intangible assets | 88,286 | 85,757 | 266,554 | 258,725 | ||
| Add: | Restructuring costs | 4,404 | 1,950 | 17,283 | 11,989 | ||
| Add: | Acquisition, integration, and transformation costs | 1,565 | 1,931 | 4,319 | 6,777 | ||
| Add: | Goodwill impairment | 12,625 | 71,763 | ||||
| Add: | Stock-based compensation | 11,616 | 16,996 | 35,528 | 64,503 | ||
| Add: | Legal settlement costs and recoveries, net | -600 | -600 | ||||
| Add: | Total Adjustments | 106,292 | 119,416 | 332,919 | 372,492 | 79 - 142 | 413 - 475 |
| Add: | Consolidated Adjusted EBITDA | 79,358 | 69,909 | 203,240 | 197,313 | $74 - 100 | $277 - 303 |
| Segment Adjusted EBITDA | Integrated Care | 74,881 | 66,068 | 196,400 | 173,897 | ||
| Segment Adjusted EBITDA | BetterHelp | 4,477 | 3,841 | 6,840 | 23,416 | ||
| Segment Adjusted EBITDA | Consolidated Adjusted EBITDA | 79,358 | 69,909 | 203,240 | 197,313 |
Balance Sheet
(In thousands, except share and per share data, unaudited)
| September 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 849,909 | 781,084 |
| Current assets: | Accounts receivable, net of allowance for doubtful accounts of $3,345 and $4,033 at September 30, 2026 and December 31, 2025, respectively | 230,949 | 192,826 |
| Current assets: | Inventories | 30,747 | 38,203 |
| Current assets: | Prepaid expenses and other current assets | 114,405 | 107,016 |
| Current assets: | Total current assets | 1,226,010 | 1,119,129 |
| Current assets: | Property and equipment, net | 24,406 | 26,972 |
| Current assets: | Goodwill | 283,190 | 283,190 |
| Current assets: | Intangible assets, net | 1,117,143 | 1,297,087 |
| Current assets: | Operating lease—right-of-use assets | 21,849 | 26,119 |
| Current assets: | Other assets | 102,477 | 105,803 |
| Current assets: | Total assets | 2,775,075 | 2,858,300 |
| Current liabilities: | Accounts payable | 46,339 | 47,967 |
| Current liabilities: | Accrued expenses and other current liabilities | 232,413 | 198,208 |
| Current liabilities: | Accrued compensation | 77,147 | 96,258 |
| Current liabilities: | Deferred revenue, current | 62,012 | 62,305 |
| Current liabilities: | Convertible senior notes, net—current | 997,593 | |
| Current liabilities: | Total current liabilities | 1,415,504 | 404,738 |
| Current liabilities: | Operating lease liabilities, net of current portion | 28,125 | 34,204 |
| Current liabilities: | Deferred revenue, net of current portion | 9,122 | 9,139 |
| Current liabilities: | Deferred taxes, net | 26,993 | 28,945 |
| Current liabilities: | Convertible senior notes, net—non-current | 994,925 | |
| Current liabilities: | Other liabilities | 608 | 643 |
| Current liabilities: | Total liabilities | 1,480,352 | 1,472,594 |
| Stockholders’ equity: | Common stock, $0.001 par value; 300,000,000 shares authorized; 182,254,430 shares and 178,315,400 shares issued and outstanding as of September 30, 2026 and December 31, 2025 respectively | 182 | 178 |
| Stockholders’ equity: | Additional paid-in capital | 17,888,783 | 17,850,478 |
| Stockholders’ equity: | Accumulated deficit | -16,559,901 | -16,430,222 |
| Stockholders’ equity: | Accumulated other comprehensive loss | -34,341 | -34,728 |
| Stockholders’ equity: | Total stockholders’ equity | 1,294,723 | 1,385,706 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 2,775,075 | 2,858,300 |
Cash Flow
Nine Months Ended September 30, — (In thousands, unaudited) (in thousands)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities: | Net loss | -129,679 | -175,179 |
| Adjustments to reconcile net loss to net cash flows from operating activities: | Goodwill impairment | 71,763 | |
| Adjustments to reconcile net loss to net cash flows from operating activities: | Amortization of intangible assets | 266,554 | 258,725 |
| Adjustments to reconcile net loss to net cash flows from operating activities: | Stock-based compensation | 35,528 | 64,503 |
| Adjustments to reconcile net loss to net cash flows from operating activities: | Depreciation of property and equipment | 7,115 | 10,514 |
| Adjustments to reconcile net loss to net cash flows from operating activities: | Amortization of right-of-use assets | 5,006 | 7,973 |
Cash Flow
Three Months Ended — (In thousands, unaudited) (in millions)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | Outlook (9) – Full Year | |
|---|---|---|---|---|---|
| Net cash provided by operating activities | 106,458 | 99,264 | 180,636 | 206,615 | $263 - 288 |
| Capital expenditures | -1,214 | -2,280 | -3,802 | -6,274 | |
| Capitalized software development costs | -29,308 | -29,038 | -91,460 | -86,862 | |
| Capex | -30,522 | -31,318 | -95,262 | -93,136 | (128) - (123) |
| Free Cash Flow | 75,936 | 67,946 | 85,374 | 113,479 | $135 - 165 |
(1) increased 14% to $79.4 million, compared to $69.9 million for Third Quarter 2025. The Integrated Care segment adjusted EBITDA increased $8.8 million and the BetterHelp segment adjusted EBITDA increased $0.6 million in Third Quarter 2026.
Nine Months Ended September 30, 2026
Revenue decreased 3% to $1,825.9 million from $1,887.7 million in the first nine months of 2025. Access fees revenue decreased 9% to $1,425.6 million while other revenue increased 26% to $400.3 million. U.S. revenue decreased 6% to $1,468.1 million while International revenue increased 7% to $357.8 million.
Integrated Care segment revenue increased 2% to $1,188.2 million in the first nine months of 2026 while BetterHelp segment revenue decreased 11% to $637.7 million.
Net loss totaled $129.7 million, or $0.72 per share, for the first nine months of 2026, compared to $175.2 million, or $1.00 per share, for the first nine months of 2025. Results for the first nine months of 2026 included amortization of intangibles of $266.6 million, or $1.48 per share pre-tax, and stock-based compensation expense of $35.5 million, or $0.20 per share pre-tax. Net loss for the first nine months of 2026 also included restructuring costs of $17.3 million, or $0.10 per share pre-tax, primarily related to severance costs.
Results for the first nine months of 2025 included amortization of intangibles of $258.7 million, or $1.47 per share pre-tax, non-cash goodwill impairment charges of $71.8 million, or $0.41 per share pre-tax, and stock-based compensation expense of $64.5 million, or $0.37 per share pre-tax. Net loss for the first nine months of 2025 also included restructuring costs related to severance costs and costs associated with office space reductions of $12.0 million, or $0.07 per share pre-tax. These items were partially offset by a discrete tax benefit of $20.1 million, or $0.11 per share, related to the completion of a research and development tax credit study and acquisition related tax benefits of $11.1 million, or $0.06 per share.
The non-cash goodwill impairment charges recorded in the first nine months of 2025 were the results of the fair value of the Integrated Care segment being less than its carrying value at the time of the acquisitions of Catapult Health, LLC and Telecare.
Adjusted EBITDA
(1)... (tred 3% to $203.2 million, compared to $197.3 million for the first nine months of 2025. The Integrated Care segment adjusted EBITDA increase of $22.5 million was offset by a $16.6 million decrease in BetterHelp segment adjusted EBITDA in the first nine months of 2026.
Capex and Cash Flow
Cash flow from operations was $106.5 million in Third Quarter 2026, compared to $99.3 million in Third Quarter 2025, and was $180.6 million in the first nine months of 2026, compared to $206.6 million in the first nine months of 2025. Capital expenditures and capitalized software development costs (together, “Capex”) were $30.5 million in Third Quarter 2026, compared to $31.3 million in Third Quarter 2025, and were $95.3 million in the first nine months of 2026, compared to $93.1 million in the first nine months of 2025.²
Free cash flow was $75.9 million in Third Quarter 2026, compared to $67.9 million in Third Quarter 2025, and was $85.4 million in the first nine months of 2026, compared to $113.5 million in the first nine months of 2025.
Financial Outlook
The outlook provided below is based on current market conditions and expectations and what we know today.
See note (2) in the Notes section that follows.³
Earnings Conference Call
The Third Quarter 2026 earnings conference call and webcast will be held Wednesday, October 28, 2026 at 5:00 p.m. E.T. The conference call can be accessed by dialing 833-461-5787 for U.S. participants and using the meeting ID # 404 870 451. For international participants, please visit the following link for global dial-in numbers, using the same meeting ID # 404 870 451: https://help.events.q4inc.com/eahc/international-dial-in-numbers. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at www.teladochealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, the information under the caption “Financial Outlook” and statements we make regarding future financial or operating results, future numbers of members, BetterHelp paying users or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, initiatives to improve our efficiency and competitiveness, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that have in the past and/or may in the future cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) a decrease in revenue from users who pay directly out-of-pocket without offsetting growth in insurance-covered services in our BetterHelp segment; (vi) changes in valuations or useful lives of our assets; (vii) changes in our abilities to recruit and retain qualified providers into our network; (viii) the impact of and risk related to impairment losses with respect to goodwill or other assets; (ix) the success of our initiatives to improve our efficiency and competitiveness; (x) imposed and threatened tariffs by the United States and its trading partners, and any resulting disruptions or inefficiencies in our supply chain; (xi) the performance of our new products, including Teladoc One; (xii) the rate and magnitude of declines in BetterHelp cash-pay users and revenue; (xiii) the extent to which insurance availability changes users’ payment choices; (xiv) available provider capacity including on a state and payer specific basis; (xv) the timing, cost and effectiveness of provider recruitment, credentialing, enrollment, activation, compensation and retention; (xvi) the performance of insurance-specific eligibility, matching, booking, scheduling, utilization, session-duration, claims and collection workflows; (xvii) the effectiveness and revenue consequences of changes in advertising and marketing spending; (xviii) the effects of BetterHelp’s reduced near term emphasis and investment outside the United States; (xix) the cost, timing and effectiveness of platform and provider-capacity investments; (xx) the margin effects of the insurance mix; and (xxi) potential impairment of BetterHelp goodwill. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.⁴
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.⁵